News Channels

19 Sep 2023 Magnet Biomedicine Emerges from Stealth with $50 Million to Advance Rational Approach to Molecular Glues with TrueGlue™ Discovery Platform
19 Sep 2023 ImmPACT Bio Doses First Patient in Phase 1/2 Trial Evaluating IMPT-314, a Bispecific CD19/CD20 CAR T-cell Therapy for the Treatment of Aggressive B-cell Lymphoma
19 Sep 2023 AIRNA Launches to Develop New Class of RNA Editing Therapeutics for Rare and Common Diseases
19 Sep 2023 MRM Health Reports Positive Topline Results from Phase 2a Clinical Study with MH002 in Mild-to-Moderate Ulcerative Colitis
19 Sep 2023 Drug Farm Doses First Patient in Phase 1 Trial for ALPK1 Inhibitor, DF-003
19 Sep 2023 Pharmanovia acquires global central nervous system (CNS) portfolio from Sanofi
19 Sep 2023 Atrial Fibrillation Study with Abelacimab Stopped Early by the Data Monitoring Committee Due to an Overwhelming Reduction in Bleeding as Compared to a DOAC (Direct Oral Anticoagulant)
19 Sep 2023 LinKinVax and Gustave Roussy Announced First Patient Dosed in Phase I/IIa Clinical Study on HPV.DCVax in HPV-positive Oropharyngeal Cancer
19 Sep 2023 Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas
19 Sep 2023 Otsuka and Astex announce that the European Commission has approved INAQOVI® (oral decitabine and cedazuridine) for the treatment of adults with newly diagnosed acute myeloid leukaemia
19 Sep 2023 ATA-200, Atamyo Therapeutics’ Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type 2C/R5, Reaches Key Milestones with the Filing of a Clinical Trial Application in Europe and a Non-Dilutive Financing from France 2030 Program
19 Sep 2023 BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab)
19 Sep 2023 BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®
19 Sep 2023 ESSA Pharma Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
19 Sep 2023 FDA Accepts for Priority Review Merck’s Supplemental New Drug Application for WELIREG® (belzutifan) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
19 Sep 2023 European Commission Approves Pfizer’s LITFULO™ for Adolescents and Adults With Severe Alopecia Areata
19 Sep 2023 Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with Lead Candidate HDP-101
18 Sep 2023 Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose
18 Sep 2023 Kite’s Car T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma
18 Sep 2023 Vividion Therapeutics starts Phase I clinical trial in advanced solid tumors with KEAP1 activator

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up